Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

SR9009 (Stenabolic): what the evidence says

Name: SR9009 (Stenabolic)
Published: 2026-10-27

At a glance

What it is: a small-molecule REV-ERB agonist from Scripps, not a peptide. ^R1 Sold online as an "exercise mimetic" and fat burner.

What the evidence says: in mice, it shifted body-clock genes, raised energy use and reduced fat in diet-induced obesity. ^R1 Muscle studies in mice linked REV-ERB-alpha to mitochondrial fitness. ^R2 No human trials have been published.

Biggest risks: unknown in people. Cells lacking both REV-ERB proteins still responded to SR9009, so its effects are not all from its claimed target. ^R3

Rating


Human Human evidence	No human data
Animal Animal / lab evidence	Limited: mouse metabolism ^R1; muscle biology ^R2; off-target effects ^R3
Regulatory	Never approved; not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page · Prohibited at all times, WADA S4.4.1 ^{R4, R5, R6, R7}
Established human dose	None

Evidence verdict: Fat loss, endurance, sleep or circadian effects in people: No human data · Mouse metabolism: Limited (mouse only) · Mechanism: Uncertain (acts without its target)

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: all evidence is from mice and cells. Its oral absorption in people has never been measured in a published study. UNVERIFIED reports of poor oral bioavailability in rodents.

What is it?

SR9009 was made to switch on REV-ERB-alpha and -beta, proteins that help run the body clock. ^R1 Related pages: SLU-PP-332, AICAR, Cardarine (GW501516).

Does it work?

Animal Mice: changed daily activity patterns and clock-gene rhythms; obese mice lost fat mass and had better blood lipids and sugar. ^R1
Animal Mice: REV-ERB-alpha controls muscle oxidative capacity; an agonist increased exercise capacity in mice. ^R2
Unknown People: no published trials.

Is it safe?

Animal In cells with both REV-ERB genes deleted, SR9009 still cut cell viability and rewired metabolism, so "REV-ERB" explanations of its effects are unreliable. ^R3
Unknown No human safety data.

Gray-market products: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: never approved; not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R5, R6, R7}
Sport: WADA S4.4.1 names SR9009 as prohibited at all times. ^R4

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
Obese mice 2012	Diet-induced obese mice	Injection	Not applicable	12 days	Fat mass down, lipids better	PMID 22460951
Mouse muscle 2013	Mice	Injection	Not applicable	Per study	Exercise capacity up	PMID 23852339
REV-ERB knockout cells 2019	Mouse hepatocytes, stem cells	In vitro	Not applicable	Not applicable	Effects without REV-ERB	PMID 31127047

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 26, 2026)

^R1 Solt LA, et al. Nature. 2012. PMID 22460951
^R2 Woldt E, et al. Nat Med. 2013. PMID 23852339
^R3 Dierickx P, et al. Proc Natl Acad Sci U S A. 2019. PMID 31127047
^R4 WADA. The 2026 Prohibited List, S4.4.1 Metabolic modulators. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R5 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R6 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R7 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use SR9009 (Stenabolic). If you are considering a gray-market product, talk to a clinician you trust first, especially if you have or have had cancer, liver disease, are pregnant, or are a tested athlete. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).